R Belshe
Overview
Explore the profile of R Belshe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gorfinkel I, Aoki F, McNeil S, Dionne M, Shafran S, Zickler P, et al.
Int J STD AIDS
. 2013 Aug;
24(5):345-9.
PMID: 23970700
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) infections continue to be among the most common and unrecognized sexually transmitted infections in the world. Although treatable, HSV-1 and HSV-2...
2.
Evans T, McElrath M, Matthews T, Montefiori D, Weinhold K, Wolff M, et al.
Vaccine
. 2001 Mar;
19(15-16):2080-91.
PMID: 11228380
Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein...
3.
Verrier F, Burda S, Belshe R, Duliege A, Excler J, Klein M, et al.
J Virol
. 2000 Oct;
74(21):10025-33.
PMID: 11024131
A human immunodeficiency virus (HIV) vaccine that will be useful in diverse geographic regions will need to induce a broad immune response characterized by cross-clade immunity. To test whether a...
4.
McElrath M, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, et al.
AIDS Res Hum Retroviruses
. 2000 Jun;
16(9):907-19.
PMID: 10875616
Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter,...
5.
Treanor J, Kotloff K, Betts R, Belshe R, Newman F, Iacuzio D, et al.
Vaccine
. 1999 Dec;
18(9-10):899-906.
PMID: 10580204
Trivalent, live, cold-adapted influenza vaccine (CAIV-T) is highly effective in the prevention of influenza in children, and a variety of monovalent and bivalent cold-adapted influenza vaccines have been efficacious in...
6.
Weinhold K, Matthews T, Graham B, Gorse G, Keefer M, McElrath M, et al.
J Infect Dis
. 1998 May;
177(5):1230-46.
PMID: 9593008
A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing...
7.
Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, et al.
J Infect Dis
. 1997 Apr;
175(4):764-74.
PMID: 9086128
The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic...
8.
BERMAN P, Eastman D, Wilkes D, NAKAMURA G, Gregory T, Schwartz D, et al.
AIDS
. 1994 May;
8(5):591-601.
PMID: 7520248
Objective: To assess similarities and differences in antibody responses to recombinant (r) HIV-1IIIB gp120 in chimpanzees, previously protected from HIV-1 infection, and human volunteers immunized in connection with a Phase...
9.
Keefer M, Belshe R, Graham B, McElrath J, Clements M, Sposto R, et al.
AIDS Res Hum Retroviruses
. 1994 Jan;
10 Suppl 2:S139-40.
PMID: 7865288
No abstract available.
10.
Schwartz D, Gorse G, Clements M, Belshe R, Izu A, Duliege A, et al.
Lancet
. 1993 Jul;
342(8863):69-73.
PMID: 8100910
A recombinant human immunodeficiency virus 1 IIIB (HIV-1IIIB) gp120 subunit vaccine (IIIB-rgp120/HIV-1, Genentech) was tested for safety and immunogenicity in a randomised, double-blind, placebo-controlled phase-I trial. HIV-1-seronegative adult volunteers received...